12:48 PM EST, 11/06/2025 (MT Newswires) -- Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) have reached agreements to reduce prices for a number of weight-loss and diabetes drugs, including Ozempic, Wegovy, Zepbound and Orforglipron under the government's TrumpRx program, the White House said Thursday.

Prices for Ozempic and Wegovy will decline to $350 from $1,000 and $1,350, respectively, while Zepbound and Orforglipron will fall to an average of $346 from $1,086 when purchased through TrumpRx, the White House said.

Price: 934.42, Change: +8.61, Percent Change: +0.93